The global orthobiologics market size was estimated at USD 6.77 billion in 2024 and is projected to reach USD 10.34 billion by 2033, growing at a CAGR of 4.74% from 2025 to 2033. The market’s growth is driven by several key factors, including the increasing number of sports injuries and road traffic accidents, a rising preference for minimally invasive treatments, the growing prevalence of orthopedic procedures, and a steadily expanding geriatric population. According to the McLeod Health report, in 2022, approximately 18,577,953 orthopedic procedures were performed in the United States alone.

Recent technological advancements have significantly reshaped the landscape of orthobiologics. Innovations such as bone graft substitutes, platelet-rich plasma (PRP) therapy, and stem cell-based treatments have revolutionized treatment methodologies. These developments are supported by sophisticated diagnostic tools like MRI and CT imaging, which aid in precise planning and execution. Additionally, the emergence of 3D printing technology enables the creation of patient-specific implants and scaffolds, while biotechnological and genetic engineering approaches are enhancing the regenerative capabilities of orthobiologic therapies, ultimately leading to improved patient outcomes and faster recovery times.

The orthobiologics market also sees active merger and acquisition strategies among leading players, aiming to broaden their offerings and cater to the increasing demand. For instance, in February 2023, Zimmer Biomet acquired Embody, an orthobiologics company specializing in soft tissue healing, for USD 155 million. Embody’s product line includes the Tapestry RC implant for rotator cuff repair and the Tapestry biointegrative implant for tendon healing.

Regulatory compliance remains a crucial component of market participation. Orthobiologic products must meet rigorous safety, quality, and efficacy standards before receiving approval. Agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) oversee regulatory frameworks to ensure safe clinical implementation, fostering trust among healthcare providers and patients.

Despite the growth in orthobiologics, traditional surgical procedures remain a valid option for certain patient populations, particularly those ineligible for advanced biologic treatments. Non-invasive pharmaceutical therapies and durable medical devices like joint implants continue to play a complementary role in managing musculoskeletal conditions.

To gain competitive advantage, market players are increasingly expanding into untapped geographical regions and investing heavily in research and development. A notable example is Orthofix Medical Inc., which received 510(k) clearance and fully launched OsteoCove, a novel bioactive synthetic graft, in October 2023.

Order a free sample PDF of the Orthobiologics Market Intelligence Study, published by Grand View Research.

Key Market Trends & Insights

• North America accounted for the largest share of the global orthobiologics market in 2024, holding 46.03%.

• The viscosupplementation segment led the market by product type with a 42.21% share in 2024.

• Spinal fusion remained the dominant application segment, contributing 48.29% to the market share in 2024.

• Hospitals emerged as the leading end-use segment in the same year.

Market Size & Forecast

• 2024 Market Size: USD 6.77 Billion

• 2033 Projected Market Size: USD 10.34 Billion

• CAGR (2025–2033): 4.74%

• North America: Largest market in 2024

• Europe: Fastest-growing market

Key Orthobiologics Company Insights

Industry leaders continue to focus on growth through strategic initiatives such as mergers & acquisitions, product diversification, and geographic expansion.

Key Orthobiologics Companies:

• Medtronic Plc
• DePuy Synthes
• Zimmer Biomet
• Stryker Corporation
• Bioventus LLC
• Anika Therapeutics, Inc.
• Orthofix, Inc.
• Globus Medical
• Arthrex, Inc.
• Bone Biologics Corp.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The orthobiologics market is evolving rapidly, driven by technological advancements, a growing elderly population, and increasing procedural volumes. With continued R&D efforts and supportive regulatory frameworks, the sector is poised for steady growth. Market leaders are strategically positioned to leverage emerging opportunities, particularly in minimally invasive and regenerative solutions, which are becoming the cornerstone of future orthopedic care.